Aquestive Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.5 | $57.6 | $50.6 | $47.7 | $50.8 |
| Operating income | -$71.1 | -$30.8 | -$15.1 | -$42.1 | -$34.7 |
| Net income | -$83.8 | -$44.1 | -$7.9 | -$54.4 | -$70.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$53.0 | -$35.9 | -$7.4 | -$10.8 | -$33.9 |
Shares outstanding 125.5M · Free float 95.1%
Annual filing data through FY ended December 31, 2025; float as of August 26, 2026.